Why D2 blockade alone falls short in schizophrenia, and what neurotransmitter, genetic and neuroimaging research means for treatment-resistant patients.
|Slideshows|July 4, 2018
- Vol 35, Issue 7
- Volume 35
- Issue 7
Silver Linings After Abuse and Neglect
Author(s)Brian Miller, MD, PhD, MPH
The neuroprotective role of resilience in patients with schizophrenia who experienced early childhood trauma is evaluated in this brief update.
Advertisement
Articles in this issue
over 8 years ago
Addressing Depression: The World’s Largest Health Problemover 8 years ago
Psychotherapeutic Interventions for Depression: Which Work Best?over 8 years ago
Multimodal Markers and Biomarkers of Treatmentover 8 years ago
A Historical Perspective on Suicideover 8 years ago
10 Meditations on Succeeding—and Flourishingover 8 years ago
Babble on Revisitedover 8 years ago
Millard Salter’s Last DayAdvertisement
Related to this article
New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Advertisement
Advertisement
Trending on Psychiatric Times
1
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
2
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Updates on CTx-1301, NDA Resubmission After FDA Complete Response Letter
5